Jett Foundation announced the launch of a capital campaign to fund the construction of Jett's Place, a premier wellness and retreat center designed as a dedicated sanctuary for individuals and families affected by Duchenne muscular dystrophy (DMD). The campaign, which sets a $10.7 million goal, has already raised over $5 million during its quiet phase, anchored by two transformative $1 million donations from the Emilson Family and ITF Therapeutics.
Located on a 10-acre campus in Norwell, Massachusetts, Jett's Place will serve as Jett Foundation's national headquarters and provide barrier-free accessibility, specialized wellness care, adaptive nature and recreation, and educational programs. The facility is being designed with input from Duchenne families to ensure it meets the unique needs of the community. Duchenne muscular dystrophy is a progressive neuromuscular disorder diagnosed during childhood that causes loss of motor, pulmonary, and cardiac function, and premature death. It affects approximately 1 in 5,000 live male births and some females, with no cure currently available.
Christine McSherry, founder and CEO of Jett Foundation, emphasized the importance of the project: 'Jett's Place will be a beacon of hope and a hub for connection, education, and wellness for the Duchenne community. We are deeply grateful to the Emilson Family and ITF Therapeutics for their visionary support, which has propelled us closer to making this dream a reality.' The Emilson Family's donation honors their son, who is living with Duchenne, while ITF Therapeutics, the U.S. affiliate of Italfarmaco Group, is committed to developing treatments for rare diseases.
The capital campaign invites broader community support to bring Jett's Place to life, with the foundation aiming to break ground in the near future. For more information about Jett Foundation and its programs, visit jettfoundation.org.
